XenoPort, Inc. (NASDAQ: XNPT), a biopharmaceutical company, focuses their efforts on developing a portfolio of internally discovered product candidates that leverage the body’s natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs. The company has directed their focus on developing and commercializing on potential treatments of central nervous system, or CNS, disorders. Their most advanced product candidate, XP13512 (also known as Solzira™), is in the process of being evaluated for the treatment of restless legs syndrome, or RLS, in a Phase 3 clinical program. For further information, visit the Company’s web site at www.xenoport.com.
- 18 years ago
QualityStocks
XenoPort, Inc. (NASDAQ: XNPT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Belden Inc. (NYSE: BDC) To Acquire RUCKUS Networks for $1.85 Billion
Belden (NYSE: BDC) announced it has entered into a definitive agreement to acquire RUCKUS Networks from Vistance Networks for approximately $1.85…
-
From Capital to Catalysts: Canamera Energy Metals Corp.’s (CSE: EMET) (OTCQB: EMETF) $10M Raise Sets the Stage for Rare Earth Exploration Momentum
Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF)and may include paid…
-
Forward Industries Inc. (NASDAQ: FWDI) Adds Digital Asset and Traditional Finance Executive Mark Brazier as Chief Financial Officer
Forward Industries has appointed experienced financial executive Mark Brazier to serve as Chief Financial Officer.…